Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan‐Malte Placke(Düsseldorf University Hospital), Selma Ugurel(Klinikum Bielefeld), Jochen Utikal(German Cancer Research Center), Ingo Stoffels(Essen University Hospital), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Klaus Griewank(Düsseldorf University Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Alexander Roesch(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Sophia Kreft(Charité - Universitätsmedizin Berlin), Joachim Klode(Essen University Hospital), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Georg Lodde(Essen University Hospital), Frederik Krefting(University of Duisburg-Essen), Julia Welzel(University Hospital Augsburg), Alpaslan Tasdogan(Düsseldorf University Hospital), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Daniel R. Engel(Essen University Hospital), Lisa Zimmer(The University of Sydney), Jürgen C. Becker(Düsseldorf University Hospital), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Mona Kimmig(Essen University Hospital), Eva Hadaschik(West German Heart and Vascular Center Essen), Jens Ulrich, Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 49
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k